百奧泰(688177.SH)半年度營收4878.64萬元 淨虧損2.44億元
格隆匯 8 月 27日丨百奧泰(688177.SH)發佈2020年半年度報告,實現營業收入為4878.64萬元,公司歸屬於母公司普通股股東的淨利潤為-24377.46萬元,研發費用為24458.99萬元,未來一段時間內,公司預期存在累計未彌補虧損並將持續虧損。公司未來仍需持續較大規模的研發投入用於在研項目完成臨牀前研究、臨牀試驗及新藥上市前準備等研發及已上市藥品的商業化推進。預計未來公司的在研藥品項目的數量會增多,且將會有更多在研產品進入臨牀III期試驗階段,因此預計未來將繼續產生較大量的研發費用,如研發費用大於商業化產品產生的利潤,將導致公司持續虧損,從而對公司的日常經營、財務狀況等方面造成重大不利影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.